Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02833350 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 578
- Enrollment target
NCT02833350 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 578 participants.
The verdict
NCT02833350, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 578 participants
- Enrollment target
Study Summary
This is a multicenter, Phase II, randomized, double-blind, placebo-controlled, active comparator (Cohort 1 only), parallel-group, dose-ranging study to evaluate the efficacy and safety of GDC-0853 in participants with moderate to severe active RA and an inadequate response to previous methotrexate (MTX) therapy (Cohort 1) or MTX and tumor necrosis factor (TNF) therapy who may have also had exposure to no more than one non-TNF inhibitor biologic (Cohort 2).
Interventions
- DRUG Placebo
- DRUG Adalimumab
- DRUG Folic Acid
- DRUG MTX
- DRUG GDC-0853
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 578 participants |
| Start Date | 2016-09-09 |
| Est. Completion | 2018-07-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02833350
The ClinicalTrials.gov registry entry for NCT02833350 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 578 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02833350 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02833350 about?
NCT02833350 is a clinical study titled "Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)". This is a multicenter, Phase II, randomized, double-blind, placebo-controlled, active comparator (Cohort 1 only), parallel-group, dose-ranging study to evaluate the efficacy and safety of GDC-0853 in participants with moderate to severe active RA and an inadequate response to previous methotrexate (...
What is the current status of trial NCT02833350?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 578 participants. The study started on 2016-09-09. Estimated completion is 2018-07-02.
What interventions are being tested in trial NCT02833350?
The interventions under investigation include: Placebo (DRUG), Adalimumab (DRUG), Folic Acid (DRUG), MTX (DRUG), GDC-0853 (DRUG).
Who is sponsoring clinical trial NCT02833350?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.